Viking Therapeutics (VKTX) Non Operating Income (2014 - 2026)

Viking Therapeutics (VKTX) has 13 years of Non Operating Income data on file, last reported at $5.8 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 41.2% year-over-year to $5.8 million; the trailing twelve-month figure through Mar 2026 stood at $29.6 million (down 32.73% YoY), and the FY2025 full-year result was $33.7 million, down 17.67% from the prior year.
• Non Operating Income retreated to $5.8 million in Q1 2026, from $7.0 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $11.8 million in Q2 2024 to a low of $154000.0 in Q1 2022.
• A 5-year average of $5.7 million and a median of $5.8 million in 2026 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income jumped 1697.23% in 2023 and sank 41.2% in 2026, its largest moves.
• Tracing VKTX's Non Operating Income over 5 years: stood at $732000.0 in 2022, then surged by 542.9% to $4.7 million in 2023, then jumped by 130.43% to $10.8 million in 2024, then plunged by 35.13% to $7.0 million in 2025, then declined by 17.56% to $5.8 million in 2026.
• Business Quant data shows VKTX's Non Operating Income at $5.8 million in Q1 2026, $7.0 million in Q4 2025, and $7.8 million in Q3 2025.